Nuclear factor kappa B pathway inhibitor composition and use of same
US8729053B2 · kind B2 · utility
0Cited by
17References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 22, 2009 |
| Grant date | May 20, 2014 |
| Priority date | — |
| Expiry date | Aug 23, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I) a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NFκB pathway using same compounds. A further embodiment of the invention provides a method of diagnosing a condition in an individual using same compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.